XTL Biopharmaceuticals Ltd. (XTLB)
| Market Cap | 7.64M |
| Revenue (ttm) | 451,000 |
| Net Income (ttm) | -1.03M |
| Shares Out | 881.39M |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 52,748 |
| Open | 0.8111 |
| Previous Close | 0.8100 |
| Day's Range | 0.7620 - 0.8300 |
| 52-Week Range | 0.7620 - 2.5700 |
| Beta | 0.92 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 12, 2026 |
About XTLB
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies ... [Read more]
Financial Performance
Financial StatementsNews
XTL Names Mr. Noam Band as its New Chief Executive Officer
Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”) announ...
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Completed a Private Placement of $1.5 ...
XTL Entered Definitive Agreement to Acquire The Social Proxy
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Plac...
XTL To Aquire The Social Proxy
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Place...
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel
Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets co...
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets co...
Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual Meeting
JERUSALEM, Sept. 20, 2021 /PRNewswire/ -- Dr. Morris C.